The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative ...

Monocytes are a type of white blood cell that helps fight infections in your body. A high monocyte level may indicate inflammation, infection, blood disorders, and other health issues. Along with ...

In this study, we tried to determine how quickly CML develops after BCR::ABL1 fusion, how growth rates might vary between individuals, and how tumour dynamics influence the clinical features of ...

These events are associated with innate training and can have long-term impacts on hematopoietic stem and progenitor cell (HSPC) development but can also compromise their function. While many ...

I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make them more aware that you need to go beyond just looking at numbers.”— ...

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia? Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with ...

US drug maker AbbVie has launched its key leukemia drug, Venetoclax, in India, marking its entry into the country's oncology market as it seeks to address the challenges of treating Acute Myeloid ...

IFN-α2 (in most centers today pegylated IFN-α2 [Peg-IFN-α2]) induces major or complete molecular remissions in a subset of JAK2V617-positive patients with essential thrombocythemia (ET) and ...

Granting of this orphan drug status in the EU is a significant milestone because it means that the COMP considered that AB8939 offers a significant benefit to people suffering from this condition in ...

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...